Analyst Ratings For Editas Medicine (NASDAQ:EDIT)
Today, Editas Medicine (NASDAQ:EDIT) stock received an upgrade by SunTrust Banks from Hold to Buy with a price target of $45.00.
Some recent analyst ratings include
- 1/23/2018-SunTrust Banks Upgrade from a “Hold ” rating to a ” Buy” rating.
- 11/7/2017-Cann Reiterated Rating of Hold.
- 11/7/2017-Cowen Reiterated Rating of Buy.
- 10/6/2017-Morgan Stanley Reiterated Rating of Equal Weight.
- 9/6/2017-Barclays initiated coverage with a Overweight rating.
Recent Insider Trading Activity For Editas Medicine (NASDAQ:EDIT)
Editas Medicine (NASDAQ:EDIT) has insider ownership of 19.40% and institutional ownership of 64.54%.
- On 1/3/2018 Katrine Bosley, Insider, sold 14,995 with an average share price of $34.15 per share and the total transaction amounting to $512,079.25.
- On 12/19/2017 Andrew A F Hack, CFO, sold 14,649 with an average share price of $24.68 per share and the total transaction amounting to $361,537.32.
- On 12/15/2017 Andrew A F Hack, CFO, sold 5,000 with an average share price of $24.31 per share and the total transaction amounting to $121,550.00.
- On 12/1/2017 Katrine Bosley, Insider, sold 8,333 with an average share price of $29.58 per share and the total transaction amounting to $246,490.14.
- On 11/20/2017 Andrew A F Hack, CFO, sold 5,000 with an average share price of $25.35 per share and the total transaction amounting to $126,750.00.
- On 11/17/2017 Andrew A F Hack, CFO, sold 5,000 with an average share price of $24.81 per share and the total transaction amounting to $124,050.00.
- On 11/1/2017 Katrine Bosley, Insider, sold 8,333 with an average share price of $23.64 per share and the total transaction amounting to $196,992.12.
Recent Trading Activity for Editas Medicine (NASDAQ:EDIT)
Shares of Editas Medicine closed the previous trading session at 34.60 down -0.02 0.06% with 677679 shares trading hands.